A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland

INTRODUCTION: Pembrolizumab monotherapy or in combination with chemotherapy are two new treatment options for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) and high (≥ 50%) programmed death ligand 1 (PD-L1) expression. We conducted a cost-effectiveness analysis for Switzer...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbier, Michaela Carla, Pardo, Esther, Panje, Cédric Michael, Gautschi, Oliver, Lupatsch, Judith Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214587/
https://www.ncbi.nlm.nih.gov/pubmed/33745093
http://dx.doi.org/10.1007/s10198-021-01282-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214587/
https://www.ncbi.nlm.nih.gov/pubmed/33745093
http://dx.doi.org/10.1007/s10198-021-01282-4

Ejemplares similares